The company sponsored a multinational study (RETRIEVE 2, 3 and 4) to evaluate the safety and efficacy of the Crux Vena Cava Filter (VCF) System*. Twenty-two sites from 4 countries, U.S., Belgium, Australia and New Zealand, enrolled 125 patients at high risk for a pulmonary embolism (PE).
The Crux VCF System demonstrated both deployment and retrieval success at 98 percent with zero percent embolization, migration and fracture.
Indications, contraindications, warnings and instructions for use are located in the product labeling supplied with each device.
*SIR/2012 – Abstract No. LB04